Sarepta Therapeutics (SRPT) Enterprise Value (2010 - 2026)

Sarepta Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$405.6 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 22.42% year-over-year to -$405.6 million; the TTM figure through Mar 2026 stood at -$405.6 million (up 22.42% YoY), while the FY2025 annual figure was -$939.6 million, up 14.26% from the prior year.
• Enterprise Value for Q1 2026 stood at -$405.6 million, up from -$939.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$242.5 million in Q3 2024, with the low at -$2.1 billion in Q3 2022.
• The 5-year median for Enterprise Value is -$1.5 billion (2024), against an average of -$1.3 billion.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 86.01% in 2024, then sank 164.96% in 2025.
• Sarepta Therapeutics' Enterprise Value stood at -$2.0 billion in 2022, then climbed by 15.74% to -$1.7 billion in 2023, then surged by 34.62% to -$1.1 billion in 2024, then advanced by 14.26% to -$939.6 million in 2025, then surged by 56.84% to -$405.6 million in 2026.
• Business Quant data shows SRPT's Enterprise Value at -$405.6 million in Q1 2026, -$939.6 million in Q4 2025, and -$642.5 million in Q3 2025.